AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

November 27, 2022

Study Completion Date

November 28, 2023

Conditions
Lung Cancer
Interventions
DRUG

Carboplatin

Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

DRUG

Paclitaxel

Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

DRUG

AZD1775

Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02513563 - AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | Biotech Hunter | Biotech Hunter